Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Welcome to BioNTech’s Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor ...

BioNTech SE, a cutting-edge global immunotherapy company, specializes in developing innovative therapies for cancer and other serious diseases through technologies like mRNA-based vaccines. In its ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

Florida Gov. Ron DeSantis is advocating for President-elect Donald Trump to tap Florida Surgeon General Joseph Ladapo for the role of HHS secretary.

Novavax is approved for children aged 12 and older. Both Moderna and Pfizer-BioNTech vaccines use messenger RNA (mRNA), which ...

The UK is making progress in developing cancer vaccines, but there are still challenges ahead, Chris Baraniuk reports The UK is on its way to becoming a hotbed of cancer vaccine trials. In May this ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...